食管癌新辅助免疫治疗联合化疗的研究进展和热点问题  

Recent Advances and Hot Spots of Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Carcinoma

作　　者：吕会来[1] 盖春月 王明博[1] 李振华[1] 李嘉宸 许石 丁伟禄 刘宇[1] 田子强[1] LYU Huilai;GAI Chunyue;WANG Mingbo;LI Zhenhua;LI Jiachen;XU Shi;DING Weilu;LIU Yu;TIAN Ziqiang(Department of Thoracic Surgery,The Fourth Hospital of Hebei Medical University,Hebei Key Laboratory of Accurate Diagnosis and Comprehensive Treatment of Esophageal Cancer,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第四医院胸外科,河北省食管癌精准诊断与综合治疗重点实验室,石家庄050011

出　　处：《肿瘤防治研究》2024年第12期994-999,共6页Cancer Research on Prevention and Treatment

基　　金：河北省自然科学基金(H2022206443);政府资助临床医学优秀人才培养项目(ZF2024118)。

摘　　要：以手术为基础的综合治疗是局部晚期食管癌的首选治疗策略,目前指南推荐的新辅助治疗方案包括新辅助化疗和新辅助放化疗。随着免疫时代到来,新辅助免疫治疗联合化疗备受关注,首个Ⅲ期研究也证实新辅助免疫联合化疗是一种有前景的治疗选择。本文将对目前新辅助免疫治疗联合化疗的研究进展和热点问题进行梳理和简要综述。Surgery-based multidisciplinary comprehensive treatment is the preferred treatment strategy for local advanced esophageal cancer.Neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy have been recommended by the Chinese Society of Clinical Oncology(CSCO)guideline.With the advent of immunotherapy,neoadjuvant immunotherapy combined with chemotherapy has received much attention,and the first phaseⅢstudy has also confirmed that neoadjuvant immunotherapy combined chemotherapy is a promising treatment option.This article will review the recent advances and hot spots of neoadjuvant immunotherapy combined with chemotherapy.

关 键 词：食管癌 新辅助治疗 免疫治疗联合化疗 

分 类 号：R735.1[医药卫生—肿瘤]